
London's 4BIO Capital unveils first close of $150M fund dedicated to advanced therapies
Orchard $ORTX. Seres $MCRB. RetroSense (acquired by Allergan). With several high profile exits under their belt, 4BIO Capital is out to find more trailblazers to back in the drug R&D world.
The VC shop has raised $50 million in the first close of what it hopes to be a $150 million second fund at the end of next year. With a focus on advanced therapies — cell and gene therapy, RNA-based therapy, targeted therapy, and the microbiome — they will devote 60% of the fund to European deals from their perch in London, while spreading the rest between Japan and the US, going into the Midwest and the South for promising ideas that might not have received as much love as those coming out of Boston.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.